The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors
- 2 January 2016
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 127 (1) , 145-153
Abstract
This study aims to evaluate the cost-effectiveness of surgical resection (S) and Cesium-131 (Cs-131) [S + Cs-131] intraoperative brachytherapy versus S and stereotactic radiosurgery (SRS) [S + SRS] for the treatment of brain metastases. Treatment records as well as hospital and outpatient charts of 49 patients with brain metastases between 2008 and 2012 who underwent S + Cs-131 (n = 24) and S + SRS (n = 25) were retrospectively reviewed. Hospital charges were compared for the single treatment in question. Means and curves of survival time were defined by the Kaplan–Meier estimator, with the cost analysis focusing on the time period of the relevant treatment. Quality adjusted life years (QALY) and Incremental cost-effectiveness ratios (ICER) were calculated for each treatment option as a measure of cost-effectiveness. The direct hospital costs of treatments per patient were: S + Cs131 = $19,271 and S + SRS = $44,219. The median survival times of S + Cs-131 and S + SRS were 15.5 and 11.3 months, and the 12 month survival rates were 61 % and 49 % (P = 0.137). The QALY for S + SRS when compared to S + Cs-131 yielded a p < 0.0001, making it significantly more cost-effective. The ICER also revealed that when compared to S + Cs-131, S + SRS was significantly inferior (p < 0.0001). S + Cs-131 is more cost-effective compared with S + SRS based on hospital charges as well as QALYs and ICER. Cost effectiveness, in addition to efficacy and risk, should factor into the comparison between these two treatment modalities for patients with surgically resectable brain metastases.Keywords
Funding Information
- National Institute of Health CTSC KL2 Comparative Effectiveness Research Award (UL1-TR000457)
This publication has 58 references indexed in Scilit:
- Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer's perspective: Stereotactic radiosurgery versus surgical resectionClinical Neurology and Neurosurgery, 2013
- The Cost-Effectiveness of Stereotactic Radiosurgery versus Surgical Resection in the Treatment of Brain Metastasis in Vietnam from the Perspective of Patients and FamiliesWorld Neurosurgery, 2012
- The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineJournal of Neuro-Oncology, 2009
- Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trialThe Lancet Oncology, 2009
- Prospective Assessment of Patient-Rated Symptoms Following Whole Brain Radiotherapy for Brain MetastasesJournal of Pain and Symptom Management, 2005
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Postoperative Radiotherapy in the Treatment of Single Metastases to the BrainJAMA, 1998
- Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgeryAnnals of Neurology, 1993
- A Randomized Trial of Surgery in the Treatment of Single Metastases to the BrainNew England Journal of Medicine, 1990
- Radiation‐induced dementia in patients cured of brain metastasesNeurology, 1989